See highlights from the Global Science Summit

Current Pipeline
CBD

BIOM • BIO017

BIOM Therapeutics is exploring an investigational Cannabidiol (CBD) approach to treating Angelman syndrome.

Discovery & DevPre-clinicalPhase 1Phase 2Phase 3To Patients

About the Program

Cannabidiol (CBD)

Investigational Drug Name
BIO017
Company Website
BIOM Therapeutics

Program News

Biom Therapeutics Receives Orphan Drug Status for BIO017 from the U.S. FDA for the treatment of Angelman Syndrome

Read More

What are you looking for?

Find information on Angelman syndrome, research, clinical trials, resources, and ways to get involved.